{"id":56297,"date":"2021-03-20T16:59:38","date_gmt":"2021-03-20T23:59:38","guid":{"rendered":"https:\/\/drduru.com\/onetwentytwo\/?p=56297"},"modified":"2021-03-20T16:59:45","modified_gmt":"2021-03-20T23:59:45","slug":"a-new-investing-opportunity-in-genetic-testing-company-invitae","status":"publish","type":"post","link":"https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/","title":{"rendered":"A New Investing Opportunity in Genetic Testing Company Invitae"},"content":{"rendered":"\n<p>I have been a fan of genetic testing company Invitae (NVTA) for six years. My interest started after I heard co-founder (and now President, CEO, and Chairman) Sean George  give a talk at the Stanford Technology Ventures Program. He titled the 2015 talk &#8220;<a href=\"https:\/\/ecorner.stanford.edu\/videos\/experience-is-your-reward-entire-talk\/\" target=\"_blank\" rel=\"noreferrer noopener\">Experience Is Your Reward<\/a>.&#8221; George talked about facing down challenges and adversity and sharing the experience in a motivated and dedicated team. I was inspired, and I was fascinated by the prospects genetic testing technology.<\/p>\n\n\n\n<iframe src=\"https:\/\/art19.com\/shows\/entrepreneurial-thought-leaders\/episodes\/c60dcd10-8127-4a87-a302-a1b2cd2e0ccc\/embed?theme=light-custom\" style=\"width: 100%; height: 200px; border: 0 none;\" scrolling=\"no\"><\/iframe>\n\n\n\n<div style=\"height:100px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>So my ears perked when I heard that Invitae recently signed a new lease in San Francisco. I got the news in the middle of last Wednesday&#8217;s Marketplace program. Here is the key quote from a segment titled &#8220;<a href=\"https:\/\/www.marketplace.org\/2021\/03\/17\/san-francisco-millions-square-feet-vacant-office-space\/\" target=\"_blank\" rel=\"noreferrer noopener\">The big empty: San Francisco is sitting on millions of square feet of vacant office space<\/a>&#8220;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>&#8220;So far though, startups are doing more window-shopping than actual leasing. A different industry is being far more aggressive scooping up space. They\u2019re still tech-ish, just not hoodies and jeans tech-ish.<\/p><p>\u201cIf you would through the lab you\u2019d see a typical diagnostic lab, and yes there\u2019s lab coats,\u201d said Ken Knight, chief operating officer at Invitae, a biotech firm that does genetic testing.<\/p><p>Earlier this year Invitae inked a deal for a&nbsp;<a rel=\"noreferrer noopener\" href=\"https:\/\/news.theregistrysf.com\/asb-leases-40000-sqft-at-444-de-haro-in-san-francisco-to-invitae\/\" target=\"_blank\">second San Francisco location<\/a>. Terms of the deal aren\u2019t public.<\/p><p>\u201cWe wouldn\u2019t have signed the lease if we didn\u2019t feel good about the opportunity,\u201d Knight said. \u201cSo yeah, we feel good about the deal.\u201d&#8221;<\/p><\/blockquote>\n\n\n\n<p>Marketplace went on to explain that biotech companies still rely on some physical presence and cannot switch to 100% remote work. Even so, I consider this news of a <strong>second<\/strong> office space as confirming evidence that Invitae&#8217;s business continues to do well.<\/p>\n\n\n\n<br><script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js\"><\/script>\n<ins class=\"adsbygoogle\" style=\"display:block; text-align:center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-1196033822186410\" data-ad-slot=\"3478942445\"><\/ins>\n<script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script><br>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The Trade<\/strong><\/h2>\n\n\n\n<p>NVTA last topped out after the company issued <a href=\"https:\/\/ir.invitae.com\/news-and-events\/press-releases\/press-release-details\/2021\/Invitae-Announces-Pricing-of-Public-Offering-of-Common-Stock\/default.aspx\" target=\"_blank\" rel=\"noreferrer noopener\">a secondary stock offering in late January at $51.50\/share<\/a>. Per <a href=\"https:\/\/drduru.com\/onetwentytwo\/2021\/01\/25\/how-to-understand-the-price-action-from-stock-offerings\/\" target=\"_blank\" rel=\"noreferrer noopener\">my rules on secondaries<\/a>, I waited out the price action. NVTA never quite recovered, so I still had no fresh position when the recent sell-off in growth stocks took NVTA down and through its 200-day moving average (DMA) (the blue line in the chart below). Expecting on-going churn, I bought a covered call position. Ahead of the expiration of the worthless March $45 call option, I rolled into a fresh short April $45 call option. The strike perfectly coincides with presumed resistance at the 50DMA (red line in the chart below). <\/p>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter size-large\"><a href=\"https:\/\/www.tradingview.com\/x\/BVA2L4ax\/\"><img decoding=\"async\" src=\"https:\/\/www.tradingview.com\/x\/BVA2L4ax\/\" alt=\"\"\/><\/a><figcaption><strong><em><a href=\"https:\/\/www.tradingview.com\/x\/BVA2L4ax\/\" target=\"_blank\" rel=\"noreferrer noopener\">Invitae<\/a> (NVTA) is pivoting around its 200DMA.<\/em><\/strong><\/figcaption><\/figure><\/div>\n\n\n\n<p>Whenever NVTA next breaks out to new all-time highs, I expect the stock to sustain upward momentum. Until then, I am content to sell call options against my new position. I would also jump at the chance to grab more shares closer to the recent lows.<\/p>\n\n\n\n<p>Be careful out there!<\/p>\n\n\n\n<p>Full disclosure: long covered call position in NVTA<\/p>\n","protected":false},"excerpt":{"rendered":"<p>I have been a fan of genetic testing company Invitae (NVTA) for six years. My interest started after I heard co-founder (and now President, CEO, and Chairman) Sean George give a talk at the Stanford Technology Ventures Program. He titled the 2015 talk &#8220;Experience Is Your Reward.&#8221; George talked about facing down challenges and adversity &#8230; <a title=\"A New Investing Opportunity in Genetic Testing Company Invitae\" class=\"read-more\" href=\"https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[300,32,511,62],"tags":[2712,2265,2648],"class_list":["post-56297","post","type-post","status-publish","format-standard","hentry","category-health-care","category-options","category-support","category-technical-analysis","tag-invitae-corporation","tag-nvta","tag-secondary-stock-offering"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>A New Investing Opportunity in Genetic Testing Company Invitae<\/title>\n<meta name=\"description\" content=\"I have been a fan of genetic testing company Invitae (NVTA) for 6 years. So my ears perked when I heard Invitae recently signed a new lease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A New Investing Opportunity in Genetic Testing Company Invitae\" \/>\n<meta property=\"og:description\" content=\"I have been a fan of genetic testing company Invitae (NVTA) for 6 years. So my ears perked when I heard Invitae recently signed a new lease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/\" \/>\n<meta property=\"og:site_name\" content=\"ONE-TWENTY TWO: Trading Financial Markets\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-20T23:59:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-20T23:59:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.tradingview.com\/x\/BVA2L4ax\/\" \/>\n<meta name=\"author\" content=\"Dr. Duru\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"A New Investing Opportunity in Genetic Testing Company Invitae\" \/>\n<meta name=\"twitter:description\" content=\"I have been a fan of genetic testing company Invitae (NVTA) for 6 years. So my ears perked when I heard Invitae recently signed a new lease.\" \/>\n<meta name=\"twitter:creator\" content=\"@drduru\" \/>\n<meta name=\"twitter:site\" content=\"@drduru\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Duru\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2021\\\/03\\\/20\\\/a-new-investing-opportunity-in-genetic-testing-company-invitae\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2021\\\/03\\\/20\\\/a-new-investing-opportunity-in-genetic-testing-company-invitae\\\/\"},\"author\":{\"name\":\"Dr. Duru\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/#\\\/schema\\\/person\\\/d9569fde6c701b021a8d958f775be9a0\"},\"headline\":\"A New Investing Opportunity in Genetic Testing Company Invitae\",\"datePublished\":\"2021-03-20T23:59:38+00:00\",\"dateModified\":\"2021-03-20T23:59:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2021\\\/03\\\/20\\\/a-new-investing-opportunity-in-genetic-testing-company-invitae\\\/\"},\"wordCount\":470,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/#\\\/schema\\\/person\\\/d9569fde6c701b021a8d958f775be9a0\"},\"image\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2021\\\/03\\\/20\\\/a-new-investing-opportunity-in-genetic-testing-company-invitae\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.tradingview.com\\\/x\\\/BVA2L4ax\\\/\",\"keywords\":[\"Invitae Corporation\",\"NVTA\",\"secondary stock offering\"],\"articleSection\":[\"Health Care\",\"Options\",\"Support\",\"Technical Analysis\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2021\\\/03\\\/20\\\/a-new-investing-opportunity-in-genetic-testing-company-invitae\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2021\\\/03\\\/20\\\/a-new-investing-opportunity-in-genetic-testing-company-invitae\\\/\",\"url\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2021\\\/03\\\/20\\\/a-new-investing-opportunity-in-genetic-testing-company-invitae\\\/\",\"name\":\"A New Investing Opportunity in Genetic Testing Company Invitae\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2021\\\/03\\\/20\\\/a-new-investing-opportunity-in-genetic-testing-company-invitae\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2021\\\/03\\\/20\\\/a-new-investing-opportunity-in-genetic-testing-company-invitae\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.tradingview.com\\\/x\\\/BVA2L4ax\\\/\",\"datePublished\":\"2021-03-20T23:59:38+00:00\",\"dateModified\":\"2021-03-20T23:59:45+00:00\",\"description\":\"I have been a fan of genetic testing company Invitae (NVTA) for 6 years. So my ears perked when I heard Invitae recently signed a new lease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2021\\\/03\\\/20\\\/a-new-investing-opportunity-in-genetic-testing-company-invitae\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2021\\\/03\\\/20\\\/a-new-investing-opportunity-in-genetic-testing-company-invitae\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2021\\\/03\\\/20\\\/a-new-investing-opportunity-in-genetic-testing-company-invitae\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.tradingview.com\\\/x\\\/BVA2L4ax\\\/\",\"contentUrl\":\"https:\\\/\\\/www.tradingview.com\\\/x\\\/BVA2L4ax\\\/\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/2021\\\/03\\\/20\\\/a-new-investing-opportunity-in-genetic-testing-company-invitae\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A New Investing Opportunity in Genetic Testing Company Invitae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/#website\",\"url\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/\",\"name\":\"ONE-TWENTY TWO: Trading Financial Markets\",\"description\":\"Exploring the poetry in financial markets for students of money and economy since the year 2000.\",\"publisher\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/#\\\/schema\\\/person\\\/d9569fde6c701b021a8d958f775be9a0\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/#\\\/schema\\\/person\\\/d9569fde6c701b021a8d958f775be9a0\",\"name\":\"Dr. Duru\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/cropped-masthead-header.jpg\",\"url\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/cropped-masthead-header.jpg\",\"contentUrl\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/cropped-masthead-header.jpg\",\"width\":900,\"height\":100,\"caption\":\"Dr. Duru\"},\"logo\":{\"@id\":\"https:\\\/\\\/drduru.com\\\/onetwentytwo\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/cropped-masthead-header.jpg\"},\"sameAs\":[\"http:\\\/\\\/www.drduru.com\\\/onetwentytwo\",\"https:\\\/\\\/www.instagram.com\\\/drduru_market_breadth\\\/\",\"https:\\\/\\\/x.com\\\/drduru\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A New Investing Opportunity in Genetic Testing Company Invitae","description":"I have been a fan of genetic testing company Invitae (NVTA) for 6 years. So my ears perked when I heard Invitae recently signed a new lease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/","og_locale":"en_US","og_type":"article","og_title":"A New Investing Opportunity in Genetic Testing Company Invitae","og_description":"I have been a fan of genetic testing company Invitae (NVTA) for 6 years. So my ears perked when I heard Invitae recently signed a new lease.","og_url":"https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/","og_site_name":"ONE-TWENTY TWO: Trading Financial Markets","article_published_time":"2021-03-20T23:59:38+00:00","article_modified_time":"2021-03-20T23:59:45+00:00","og_image":[{"url":"https:\/\/www.tradingview.com\/x\/BVA2L4ax\/","type":"","width":"","height":""}],"author":"Dr. Duru","twitter_card":"summary_large_image","twitter_title":"A New Investing Opportunity in Genetic Testing Company Invitae","twitter_description":"I have been a fan of genetic testing company Invitae (NVTA) for 6 years. So my ears perked when I heard Invitae recently signed a new lease.","twitter_creator":"@drduru","twitter_site":"@drduru","twitter_misc":{"Written by":"Dr. Duru","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/#article","isPartOf":{"@id":"https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/"},"author":{"name":"Dr. Duru","@id":"https:\/\/drduru.com\/onetwentytwo\/#\/schema\/person\/d9569fde6c701b021a8d958f775be9a0"},"headline":"A New Investing Opportunity in Genetic Testing Company Invitae","datePublished":"2021-03-20T23:59:38+00:00","dateModified":"2021-03-20T23:59:45+00:00","mainEntityOfPage":{"@id":"https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/"},"wordCount":470,"commentCount":0,"publisher":{"@id":"https:\/\/drduru.com\/onetwentytwo\/#\/schema\/person\/d9569fde6c701b021a8d958f775be9a0"},"image":{"@id":"https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/#primaryimage"},"thumbnailUrl":"https:\/\/www.tradingview.com\/x\/BVA2L4ax\/","keywords":["Invitae Corporation","NVTA","secondary stock offering"],"articleSection":["Health Care","Options","Support","Technical Analysis"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/","url":"https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/","name":"A New Investing Opportunity in Genetic Testing Company Invitae","isPartOf":{"@id":"https:\/\/drduru.com\/onetwentytwo\/#website"},"primaryImageOfPage":{"@id":"https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/#primaryimage"},"image":{"@id":"https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/#primaryimage"},"thumbnailUrl":"https:\/\/www.tradingview.com\/x\/BVA2L4ax\/","datePublished":"2021-03-20T23:59:38+00:00","dateModified":"2021-03-20T23:59:45+00:00","description":"I have been a fan of genetic testing company Invitae (NVTA) for 6 years. So my ears perked when I heard Invitae recently signed a new lease.","breadcrumb":{"@id":"https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/#primaryimage","url":"https:\/\/www.tradingview.com\/x\/BVA2L4ax\/","contentUrl":"https:\/\/www.tradingview.com\/x\/BVA2L4ax\/"},{"@type":"BreadcrumbList","@id":"https:\/\/drduru.com\/onetwentytwo\/2021\/03\/20\/a-new-investing-opportunity-in-genetic-testing-company-invitae\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/drduru.com\/onetwentytwo\/"},{"@type":"ListItem","position":2,"name":"A New Investing Opportunity in Genetic Testing Company Invitae"}]},{"@type":"WebSite","@id":"https:\/\/drduru.com\/onetwentytwo\/#website","url":"https:\/\/drduru.com\/onetwentytwo\/","name":"ONE-TWENTY TWO: Trading Financial Markets","description":"Exploring the poetry in financial markets for students of money and economy since the year 2000.","publisher":{"@id":"https:\/\/drduru.com\/onetwentytwo\/#\/schema\/person\/d9569fde6c701b021a8d958f775be9a0"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/drduru.com\/onetwentytwo\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/drduru.com\/onetwentytwo\/#\/schema\/person\/d9569fde6c701b021a8d958f775be9a0","name":"Dr. Duru","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2018\/09\/cropped-masthead-header.jpg","url":"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2018\/09\/cropped-masthead-header.jpg","contentUrl":"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2018\/09\/cropped-masthead-header.jpg","width":900,"height":100,"caption":"Dr. Duru"},"logo":{"@id":"https:\/\/drduru.com\/onetwentytwo\/wp-content\/uploads\/2018\/09\/cropped-masthead-header.jpg"},"sameAs":["http:\/\/www.drduru.com\/onetwentytwo","https:\/\/www.instagram.com\/drduru_market_breadth\/","https:\/\/x.com\/drduru"]}]}},"_links":{"self":[{"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/posts\/56297","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/comments?post=56297"}],"version-history":[{"count":5,"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/posts\/56297\/revisions"}],"predecessor-version":[{"id":56302,"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/posts\/56297\/revisions\/56302"}],"wp:attachment":[{"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/media?parent=56297"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/categories?post=56297"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drduru.com\/onetwentytwo\/wp-json\/wp\/v2\/tags?post=56297"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}